surmount-1 trial tirzepatide non-diabetic weight loss once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1 Trial - Cardionerds Twitter

Always consult with your healthcare professional before drinking wine while on tirzepatide

Researchers studying tirzepatide for weight loss started noticing inflammatory markers dropping, and not just because participants were losing weight

For insulin, the complete-case analysis yielded between-group differences of similar magnitude but with smaller p-values than the multiple-imputation analysis

Increase fluid intake if you experience diarrhea or vomiting

The much larger, headline-grabbing numbers associated with cagrilintide in the press figures in the low-to-mid 20% range come from Phase 3 trials of CagriSema , the combination with semaglutide, and are company-reported topline results, not standalone-cagrilintide data and not the peer-reviewed Phase 2 result cited above